Symposia & Webinars

Statin/ezetimibe combinations: data and evidence, for which patients

 

The presentation by Alberto Zambon about statin/ezetimibe combinations starts with evidence on efficacy of LDL-lowering therapies down to below 1.4 mmol/L (IMPROVE_IT trial). Data suggest that:

  • Every 39 mg/dl reduction in LDL-C reduces annual CV risk by up to 28%, regardless of mechanism.
  • Ezetimibe-statin combination therapy was associated with greater cardiovascular benefits in patients with diabetes than in those without diabetes.
  • The benefit of ezetimibe is consistent in ACS patients with and without polyvascular disease and type 2 DM.

After some evidence from the Jupier TRIAL about sub-optimal cholesterol response to statin therapy and the future risk of cardiovascular disease, the presentation ends with the emerging concepts of individualized cholesterol-lowering therapy.

This video is part of the session “Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy” held virtually at ESC congress 2020 on Monday August 31st, 2020, with co-chairs A. Zambon and L. Perez de Isla.

View also the other parts of the congress session: